MedTrace Logo

Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression

NCT01479829 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2024-04-29

Study results available
· View outcomes & findings →

Summary

This project will attempt to enhance and augment the antidepressant efficacy of a commonly used antidepressant in poorly responding bipolar depressed patients.

Conditions

Interventions

DRUG

Escitalopram

Escitalopram is a Selective Serotonin Reuptake Inhibitor (SSRI)

DRUG

Celecoxib

Celecoxib is a nonsteroidal anti-inflammatory drug

DRUG

Placebo

Placebo is a manufactured capsule with no active ingredient

Sponsors & Collaborators

  • Stanley Medical Research Institute

    collaborator OTHER

  • Loyola University

    lead OTHER

Principal Investigators

  • Angelo Halaris, MD, PhD · Loyola Univeristy Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-23
Primary Completion
2017-12-28
Completion
2018-01-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01479829 on ClinicalTrials.gov